Lorlatinib is a third-gen ALK and ROS1 inhibitor. It’s used to treat advanced NSCLC that’s ALK-positive and has grown despite earlier ALK inhibitors. It zeros in on those ALK and ROS1 kinases to stop cancer tumors from growing.
You can get Lorlatinib in 25mg and 100mg strengths. The usual dose is 100mg, taken every day. The tablets have a coating and can be taken with or without eating.
They come in bottles, each with 30 tablets.
